Kate Burba

SAN DIEGO — Retreatment with nucleos(t)ide analogue therapy for relapse after withdrawal did not affect hepatitis B surface antigen seroclearance among patients with chronic HBV infection, according to a researcher at The Liver Meeting. “Nucleos(t)ide analogue (NA) therapy can effectively inhibit replication of HBV and improve clinical outcomes in individuals with chronic HBV

SAN DIEGO — Preemptive continuous renal replacement therapy after therapeutic plasma exchange reduced mortality and improved other outcomes in patients with acute liver failure and cerebral edema, according to data from The Liver Meeting. “In this part of the world, live-donor liver transplantation is the more active transplant program; however, it is not available because of the lack

SAN DIEGO — Once-daily FXR314 was well-tolerated and safely improved liver fat content and biochemical markers over 16 weeks in patients with metabolic dysfunction-associated steatohepatitis, according to research at The Liver Meeting. “FXR314 is a novel, nonsteroidal non-bile acid [FXR (farnesoid X receptor)] agonist with a unique chemotype and functionality distinct from other FXR

Baseline concomitant exposure to commonly used medications, such as corticosteroids and 5-aminosalicylates, did not significantly affect clinical and endoscopic outcomes during induction therapy in ulcerative colitis, data analysis showed. “Several medications which may have an impact on IBD-related inflammation are routinely used at trial entry including corticosteroids, immunomodulators

Older age but not high comorbidity burden was significantly associated with overall survival among patients with hepatocellular carcinoma, even those with early-stage disease, according to study results. “Patient characteristics, including age and comorbidity, can impact treatment eligibility and competing risks of mortality, thereby limiting the benefits of cancer screening,” Mounika

The expansion of safe and effective FDA-approved biosimilars for inflammatory bowel disease set to launch in early 2025 may improve access to care, with the potential to reduce health care costs and revolutionize the treatment landscape.Within the last year, the FDA has approved several notable agents including the sixth biosimilar for Stelara (ustekinumab, Janssen) and the third interchangeable

Throughout 2024, experts in the fields of gastroenterology and hepatology weighed in on cutting edge research, emerging trends and policies, as well as clinical innovations shaping the future of patient care.Hot topic interviews included the AGA’s opinion on UnitedHealthcare’s Gold Card program for GI endoscopy, concerns about rising rates of anal cancer and metastatic stomach cancer,

More women than ever have joined gastroenterology in the past 20 years — a staggering 219% increase according to the Association of American Medical Colleges — yet they continue to make up only 21% of active physicians in the specialty.While the steady expansion of women physicians is evident in the field of gastroenterology and medicine overall, data have shown that marked

SAN FRANCISCO — Patient activation, earned trust and health literacy at patient, provider and health system levels are critical to overcoming health disparities among pediatric patients with inflammatory bowel disease, noted a presenter.“Disparities in health in the U.S. have a lot to do with the interplay of these [socioeconomic] determinants, particularly race and ethnicity, and how

SAN FRANCISCO — Patients with inflammatory bowel disease remain at higher risk for mental health disorders, but training support staff to recognize the symptoms could be key to preventing further traumatization, noted a presenter here. “The mental health burden in IBD is really significant across most mental health conditions,” Katrina S. Hacker, PhD, assistant professor of